Deborah A Robins

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 8

Top Topics

Palliative Care

Top Venues

Alimentary pharmacology & therapeutics

Diabetes, obesity & metabolism

This page only lists publications with an associated author ORCID identifier.

Publications

Raj K Vuppalanchi, Stephen Caldwell, Arun J Sanyal, Amir Nikooie, Yuanyuan Tang, Deborah A Robins, Bram Brouwers, Mark L Hartman
Randomised clinical trial: Design of the SYNERGY-NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction-associated steatohepatitis and modification of screening strategy to reduce screen failures. Alimentary pharmacology & therapeutics (2024)
Raj K Vuppalanchi, Stephen Caldwell, Arun J Sanyal, Amir Nikooie, Yuanyuan Tang, Deborah A Robins, Bram Brouwers, Mark L Hartman
Randomised clinical trial: Design of the SYNERGY-NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction-associated steatohepatitis and modification of screening strategy to reduce screen failures. Alimentary pharmacology & therapeutics 60 (1) (2024)
Raj K Vuppalanchi, Stephen Caldwell, Arun J Sanyal, Amir Nikooie, Yuanyuan Tang, Deborah A Robins, Bram Brouwers, Mark L Hartman
Randomised clinical trial: Design of the SYNERGY-NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction-associated steatohepatitis and modification of screening strategy to reduce screen failures. Alimentary pharmacology & therapeutics 60 (1) (2024)
Raj K Vuppalanchi, Stephen Caldwell, Arun J Sanyal, Amir Nikooie, Yuanyuan Tang, Deborah A Robins, Bram Brouwers, Mark L Hartman
Randomised clinical trial: Design of the SYNERGY-NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction-associated steatohepatitis and modification of screening strategy to reduce screen failures. Alimentary pharmacology & therapeutics 60 (1) (2024)
Jonathan M Wilson, Yanzhu Lin, M Jane Luo, Gary Considine, Amy L Cox, Lenden M Bowsman, Deborah A Robins, Axel Haupt, Kevin L Duffin, Giacomo Ruotolo
The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc analysis. Diabetes, obesity & metabolism 24 (1) (2021)
Mark L Hartman, Arun J Sanyal, Rohit Loomba, Jonathan M Wilson, Amir Nikooienejad, Ross Bray, Chrisanthi A Karanikas, Kevin L Duffin, Deborah A Robins, Axel Haupt
Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes. Diabetes care 43 (6) (2020)
Juan Pablo Frias, Michael A Nauck, Joanna Van, Charles Benson, Ross Bray, Xuewei Cui, Zvonko Milicevic, Shweta Urva, Axel Haupt, Deborah A Robins
Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens. Diabetes, obesity & metabolism 22 (6) (2020)
Jonathan M Wilson, Amir Nikooienejad, Deborah A Robins, William C Roell, Jeffrey S Riesmeyer, Axel Haupt, Kevin L Duffin, Marja-Riitta Taskinen, Giacomo Ruotolo
The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes. Diabetes, obesity & metabolism 22 (12) (2020)